A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-08-25
Adverse events
Grade 3 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-09-26 (study day 26); relationship: not assessed
Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-10-22 (study day 52); relationship: not assessed; serious criteria: life-threatening
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 54); relationship: not assessed
Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-30 (study day 60); relationship: N
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-16 (study day 107); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 212); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-05-05 (study day 248); relationship: not assessed
Data queries
No data queries.